Showing papers by "Carl Erik Mogensen published in 1996"
TL;DR: Motor performance is substantially impaired in long-term IDDM patients, and the weakness is related to the presence of neuropathy but not to albuminuria or retinopathy per se.
Abstract: The isokinetic muscle strength in 56 IDDM patients with > 20 years of diabetes duration and in their individually sex-, age-, weight-, and height-matched control subjects was assessed. Peak torque of foot dorsal and plantar flexion and knee and wrist extension and flexion was measured. The neuropathic condition was assessed by a neurological disability score, a neuropathy symptom score, nerve conduction studies, and quantitative sensory examination. All results were summed to obtain a neuropathy rank-sum score for each patient. According to their renal albumin excretion, the patients were classified to have normo-, micro-, or macroalbuminuria. In addition, according to their retinal status, patients were classified as having no, simple, or proliferative retinopathy. The IDDM patients had a 21% reduction of muscle strength of both ankle dorsal ( P ™4 ) and plantar flexors ( P P P r = −0.66, P ™7 ) and plantar flexors ( r = −0.51, P r = −0.51, P r = −0.44, P r = −0.41, P r = 0). Neither were there any relationships between muscle strength at the ankle and knee and the degree of albuminuria or retinopathy. In conclusion, motor performance is substantially impaired in long-term IDDM patients, and the weakness is related to the presence of neuropathy but not to albuminuria or retinopathy per se.
188 citations
Rabin Medical Center1, University of Helsinki2, Autonomous University of Barcelona3, Aarhus University4, Medisch Spectrum Twente5, Imperial College London6, University of Oslo7, Guy's and St Thomas' NHS Foundation Trust8, West Hertfordshire Hospitals NHS Trust9, Rutgers University10, University of Connecticut11, IBM12, Houston Methodist Hospital13, Tufts University14, Henry Ford Health System15, Harvard University16, Washington University in St. Louis17, University of Texas at Austin18, Georgetown University19
TL;DR: Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects.
Abstract: In insulin-dependent diabetes mellitus (IDDM), microalbuminuria predicts renal and cardiovascular disease. We report a combined analysis of 235 normotensive IDDM patients with microalbuminuria who participated in two 24-month double-blind, randomised, placebo-controlled trials to assess the effects of captopril 50 mg twice daily on the progression to overt clinical albuminuria. Of the 225 patients who were evaluable on an intent to treat basis, 25 of 114 placebo-treated patients (21.9%) and 8 of 111 captopril-treated patients (7.2%) progressed to persistent clinical albuminuria. The risk of progression over 24 months was significantly reduced by captopril (p = 0.004) with a risk reduction of 69.2% (95% confidence interval (CI): 31.7 to 86.1%). This degree of risk reduction remained at the same level (62.9% [16.1-83.6%], p = 0.017) after adjustment for differences in time-varying mean arterial blood pressure. Albumin excretion rate increased by an average of 14.2% [3.1-26.5%] per year in the placebo-treated group compared with a reduction of 9.6% [-18.6-0.4%] per year in the captopril-treated group (p = 0.002). The rate of fall of creatinine clearance tended to be faster in the placebo-treated group than in the captopril-treated group (-6.4 [-10.2--2.5] vs -1.4 [-5.3-2.6] ml . min(-1). 1.73 m(-2), p = 0.07). Baseline albumin excretion rate (p < 0.0001) and glycated haemoglobin (p = 0.03) were independent predictors of progression to clinical albuminuria and changes in mean arterial blood pressure (p = 0.02) and serum cholesterol level (p = 0.003) were significantly associated with percentage changes in albumin excretion rate. Captopril reduces the risk of progression to overt nephropathy in IDDM patients with microalbuminuria, an effect partly independent of its blood pressure-lowering effects.
156 citations
TL;DR: The present volume collects the contributions to the Symposium organised in original studies, reports, clinical trial designs and short reviews, Hopefully, for both depth and width these proceedings will stimulate clinical and research work in NIDDM.
Abstract: is an increasing and alarming health problem throughout the world, also in developing countries, especially in the Far East. The treatment of patients with NIDDM is clearly important, both in the early phase of the disease and, obviously, when late complications have developed. The latter present an increasing burden which is challenging physicians all over the world. The aim of the Symposium was to survey origin, mechanisms and natural course of NIDDM complications, in particular vascular and renal damage. The discussion also focussed on ways in which quality of life and longevity in these patients could be improved. The present volume collects the contributions to the Symposium organised in original studies, reports, clinical trial designs and short reviews. Hopefully, for both depth and width these proceedings will stimulate clinical and research work in NIDDM. The staff at the editorial office in Pisa have worked hard on this Special Issue and Hoechst Marion Roussel have provided an educational grant to support the meeting and to cover publication costs. To both, the organisers and the editors would like to express their sincere thanks.
1 citations